34 related articles for article (PubMed ID: 24853808)
1. Novel PEGylated Lipid Nanoparticles Have a High Encapsulation Efficiency and Effectively Deliver MRTF-B siRNA in Conjunctival Fibroblasts.
Sanghani A; Kafetzis KN; Sato Y; Elboraie S; Fajardo-Sanchez J; Harashima H; Tagalakis AD; Yu-Wai-Man C
Pharmaceutics; 2021 Mar; 13(3):. PubMed ID: 33805660
[TBL] [Abstract][Full Text] [Related]
2. Real-time trafficking of PEGylated liposomes in the rodent focal brain ischemia analyzed by positron emission tomography.
Fukuta T; Ishii T; Asai T; Nakamura G; Takeuchi Y; Sato A; Agato Y; Shimizu K; Akai S; Fukumoto D; Harada N; Tsukada H; Kawaguchi AT; Oku N
Artif Organs; 2014 Aug; 38(8):662-6. PubMed ID: 25295359
[TBL] [Abstract][Full Text] [Related]
3. The Multiple Functions of HB-EGF in Female Reproduction and Related Cancer: Molecular Mechanisms and Targeting Strategies.
Zhang Y; Tang L; Liu H; Cheng Y
Reprod Sci; 2024 Feb; ():. PubMed ID: 38424408
[TBL] [Abstract][Full Text] [Related]
4. mRNA as a medicine in nephrology: the future is now.
Granata S; Stallone G; Zaza G
Clin Kidney J; 2023 Dec; 16(12):2349-2356. PubMed ID: 38046026
[TBL] [Abstract][Full Text] [Related]
5. Effect of the amount of cationic lipid used to complex siRNA on the cytotoxicity and proinflammatory activity of siRNA-solid lipid nanoparticles.
Hanafy MS; Dao HM; Xu H; Koleng JJ; Sakran W; Cui Z
Int J Pharm X; 2023 Dec; 6():100197. PubMed ID: 37521246
[TBL] [Abstract][Full Text] [Related]
6. Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers.
Subhan MA; Filipczak N; Torchilin VP
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513882
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in siRNA delivery mediated by lipid-based nanoparticles.
Yonezawa S; Koide H; Asai T
Adv Drug Deliv Rev; 2020; 154-155():64-78. PubMed ID: 32768564
[TBL] [Abstract][Full Text] [Related]
8. Brain targeted delivery of anticancer drugs: prospective approach using solid lipid nanoparticles.
Anand A; Sugumaran A; Narayanasamy D
IET Nanobiotechnol; 2019 Jun; 13(4):353-362. PubMed ID: 31171738
[TBL] [Abstract][Full Text] [Related]
9. Targeted Delivery of siRNA Therapeutics to Malignant Tumors.
Leng Q; Woodle MC; Mixson AJ
J Drug Deliv; 2017; 2017():6971297. PubMed ID: 29218233
[TBL] [Abstract][Full Text] [Related]
10. Antibody fragments as nanoparticle targeting ligands: a step in the right direction.
Richards DA; Maruani A; Chudasama V
Chem Sci; 2017 Jan; 8(1):63-77. PubMed ID: 28451149
[TBL] [Abstract][Full Text] [Related]
11. Surface plasmon resonance as a high throughput method to evaluate specific and non-specific binding of nanotherapeutics.
Schneider CS; Bhargav AG; Perez JG; Wadajkar AS; Winkles JA; Woodworth GF; Kim AJ
J Control Release; 2015 Dec; 219():331-344. PubMed ID: 26415854
[TBL] [Abstract][Full Text] [Related]
12. Lipid-Based Nanocarriers for RNA Delivery.
Xue HY; Guo P; Wen WC; Wong HL
Curr Pharm Des; 2015; 21(22):3140-7. PubMed ID: 26027572
[TBL] [Abstract][Full Text] [Related]
13. Current status of gene therapy for breast cancer: progress and challenges.
McCrudden CM; McCarthy HO
Appl Clin Genet; 2014; 7():209-20. PubMed ID: 25419154
[TBL] [Abstract][Full Text] [Related]
14. Antibody-modified lipid nanoparticles for selective delivery of siRNA to tumors expressing membrane-anchored form of HB-EGF.
Okamoto A; Asai T; Kato H; Ando H; Minamino T; Mekada E; Oku N
Biochem Biophys Res Commun; 2014 Jul; 449(4):460-5. PubMed ID: 24853808
[TBL] [Abstract][Full Text] [Related]
15. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
[TBL] [Abstract][Full Text] [Related]
16. Development of anti-HB-EGF immunoliposomes for the treatment of breast cancer.
Nishikawa K; Asai T; Shigematsu H; Shimizu K; Kato H; Asano Y; Takashima S; Mekada E; Oku N; Minamino T
J Control Release; 2012 Jun; 160(2):274-80. PubMed ID: 22020380
[TBL] [Abstract][Full Text] [Related]
17. Cell-penetrating peptide-conjugated lipid nanoparticles for siRNA delivery.
Asai T; Tsuzuku T; Takahashi S; Okamoto A; Dewa T; Nango M; Hyodo K; Ishihara H; Kikuchi H; Oku N
Biochem Biophys Res Commun; 2014 Feb; 444(4):599-604. PubMed ID: 24486551
[TBL] [Abstract][Full Text] [Related]
18. [Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device].
Sakurai Y
Yakugaku Zasshi; 2019; 139(11):1357-1363. PubMed ID: 31685731
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
